Lead sponsor
Jiangsu HengRui Medicine Co., Ltd.
9 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.
9
Trials led
1
Active
1,260
Total enrollment
9
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1
4
Phase 2
4
Phase 3
1
Trials by status
Active, not recruiting
1
Completed
6
Unknown
2
Trials led
TrialKey I/E criterionPhaseStatusEnrollment
A Trial Comparing the Efficacy and Safety of HR17031 Injection to INS068 Injection and to SHR20004 Injection in Patients With Type 2 DiabetesBMI 20-40Ph 2Unknown455
The Effect of SHR20004（Noiiglutide ） on Body Weight in Obese Subjects Without DiabetesBMI 28-40Ph 2Unknown254
The Experiment of Noiiglutide Injection in Type 2 Diabetes PatientsBMI ≤45Ph 3Active, not recruiting137
A Phase 2 Study to Evaluate the Efficacy and Safety of HS-20004 in Type 2 Diabetes Subjects.BMI 23-35Ph 2Completed128
A PK/PD Study of Polyethylene Glycol Loxenatide in Patients With Type 2 DiabetesBMI 19-35Ph 2Completed120
A Phase I Study of Polyethylene Glycol Loxenatide in Patients With Type 2 DiabetesBMI 19-35Ph 1Completed64